OncoCyte (OCX) Competitors $3.10 +0.02 (+0.78%) Closing price 03:58 PM EasternExtended Trading$3.10 +0.00 (+0.03%) As of 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock OCX vs. MAZE, ORIC, CMPS, TKNO, HRTX, AUTL, ARCT, CKPT, ALLO, and OLMAShould you be buying OncoCyte stock or one of its competitors? The main competitors of OncoCyte include Maze Therapeutics (MAZE), ORIC Pharmaceuticals (ORIC), COMPASS Pathways (CMPS), Alpha Teknova (TKNO), Heron Therapeutics (HRTX), Autolus Therapeutics (AUTL), Arcturus Therapeutics (ARCT), Checkpoint Therapeutics (CKPT), Allogene Therapeutics (ALLO), and Olema Pharmaceuticals (OLMA). These companies are all part of the "pharmaceutical products" industry. OncoCyte vs. Maze Therapeutics ORIC Pharmaceuticals COMPASS Pathways Alpha Teknova Heron Therapeutics Autolus Therapeutics Arcturus Therapeutics Checkpoint Therapeutics Allogene Therapeutics Olema Pharmaceuticals OncoCyte (NASDAQ:OCX) and Maze Therapeutics (NASDAQ:MAZE) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, media sentiment, profitability, institutional ownership, community ranking, valuation and earnings. Does the MarketBeat Community favor OCX or MAZE? OncoCyte received 6 more outperform votes than Maze Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Maze Therapeutics an outperform vote while only 10.53% of users gave OncoCyte an outperform vote. CompanyUnderperformOutperformOncoCyteOutperform Votes1210.53%Underperform Votes10289.47% Maze TherapeuticsOutperform Votes6100.00% Underperform VotesNo Votes Does the media favor OCX or MAZE? In the previous week, OncoCyte had 3 more articles in the media than Maze Therapeutics. MarketBeat recorded 5 mentions for OncoCyte and 2 mentions for Maze Therapeutics. Maze Therapeutics' average media sentiment score of 0.62 beat OncoCyte's score of 0.32 indicating that Maze Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment OncoCyte 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Maze Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend OCX or MAZE? OncoCyte presently has a consensus target price of $4.42, indicating a potential upside of 42.29%. Maze Therapeutics has a consensus target price of $25.67, indicating a potential upside of 141.68%. Given Maze Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Maze Therapeutics is more favorable than OncoCyte.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score OncoCyte 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67Maze Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 2 Strong Buy rating(s) 3.40 Is OCX or MAZE more profitable? Maze Therapeutics has a net margin of 0.00% compared to OncoCyte's net margin of -6,122.29%. Maze Therapeutics' return on equity of 0.00% beat OncoCyte's return on equity.Company Net Margins Return on Equity Return on Assets OncoCyte-6,122.29% -269.32% -59.71% Maze Therapeutics N/A N/A N/A Do insiders & institutionals believe in OCX or MAZE? 55.3% of OncoCyte shares are owned by institutional investors. 1.6% of OncoCyte shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has higher earnings and valuation, OCX or MAZE? Maze Therapeutics has higher revenue and earnings than OncoCyte. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOncoCyte$1.88M47.19-$27.78M-$4.40-0.71Maze Therapeutics$167.50M2.78N/AN/AN/A SummaryMaze Therapeutics beats OncoCyte on 10 of the 15 factors compared between the two stocks. Get OncoCyte News Delivered to You Automatically Sign up to receive the latest news and ratings for OCX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OCX vs. The Competition Export to ExcelMetricOncoCyteDiagnostic substances IndustryMedical SectorNASDAQ ExchangeMarket Cap$88.77M$2.58B$5.49B$7.95BDividend YieldN/A0.75%5.11%4.22%P/E Ratio-0.717.7222.6218.58Price / Sales47.1948.44397.85103.49Price / CashN/A15.7538.1834.62Price / Book1.253.756.744.25Net Income-$27.78M-$65.73M$3.22B$248.18M7 Day Performance-8.44%0.04%1.59%1.36%1 Month Performance3.47%-2.47%4.09%3.85%1 Year Performance21.73%-10.85%15.98%5.37% OncoCyte Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OCXOncoCyte2.1777 of 5 stars$3.10+0.8%$4.42+42.3%+23.7%$88.77M$1.88M-0.71120News CoverageGap UpMAZEMaze TherapeuticsN/A$8.38+2.1%$25.67+206.3%N/A$367.01M$167.50M0.00121Gap UpORICORIC Pharmaceuticals3.9858 of 5 stars$5.09-0.2%$18.86+270.5%-35.3%$361.53MN/A-2.8080Upcoming EarningsNews CoverageCMPSCOMPASS Pathways2.4277 of 5 stars$3.88+1.6%$20.20+420.6%-53.6%$359.57MN/A-1.76120Upcoming EarningsNews CoverageTKNOAlpha Teknova1.8897 of 5 stars$6.71+3.4%$8.50+26.7%+274.7%$358.56M$37.75M-9.07240Upcoming EarningsNews CoveragePositive NewsHRTXHeron Therapeutics3.727 of 5 stars$2.33+1.3%$5.50+136.1%+4.3%$354.93M$144.29M-12.94300Upcoming EarningsNews CoverageAUTLAutolus Therapeutics2.7227 of 5 stars$1.39+4.5%$9.32+570.5%-61.7%$353.91M$10.12M-1.15330Gap UpARCTArcturus Therapeutics2.9847 of 5 stars$12.82-0.7%$59.20+361.8%-49.9%$347.68M$138.39M-5.77180News CoveragePositive NewsCKPTCheckpoint Therapeutics2.4082 of 5 stars$4.11+0.2%$4.33+5.4%+195.7%$344.27M$41,000.00-2.2310Positive NewsALLOAllogene Therapeutics3.4292 of 5 stars$1.57+1.3%$9.29+491.6%-39.1%$341.11M$22,000.00-1.01310Positive NewsOLMAOlema Pharmaceuticals2.4762 of 5 stars$4.89-0.4%$27.67+465.8%-49.3%$334.15MN/A-2.2370Upcoming EarningsAnalyst ForecastNews Coverage Related Companies and Tools Related Companies Maze Therapeutics Alternatives ORIC Pharmaceuticals Alternatives COMPASS Pathways Alternatives Alpha Teknova Alternatives Heron Therapeutics Alternatives Autolus Therapeutics Alternatives Arcturus Therapeutics Alternatives Checkpoint Therapeutics Alternatives Allogene Therapeutics Alternatives Olema Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OCX) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OncoCyte Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share OncoCyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy OCX Stock Free OCX Stock Alerts